Jupiter Acquisition, a week after scheduling a vote for its proposed merger with Filament Health, filed a proxy seeking a deadline extension up to June 2024. The extension vote is set for Dec. 14. The merger vote on Filament was announced as Dec. 5.
The deal values Filament at an equity value of approximately $176 million, and had been expected to close by the end of this year, subject to shareholder approvals and other closing conditions.
Filament is a natural psychedelic drug development company focused on the treatment of substance use disorders. Read more.
